[EN] THIOPHENE DERIVATIVES FOR THE TREATMENT OF DISORDERS CAUSED BY IGE<br/>[FR] DÉRIVÉS DE THIOPHÈNE POUR LE TRAITEMENT DE TROUBLES PROVOQUÉS PAR IGE
申请人:UCB BIOPHARMA SRL
公开号:WO2019243550A1
公开(公告)日:2019-12-26
Thiophene derivatives of formula (I) and a pharmaceutically acceptable salt thereof are provided. These compounds have utility for the treatment or prevention of disorders caused by IgE, such as allergy, type 1 hypersensitivity or familiar sinus inflammation.
The invention provides a compound of Formula (I)
pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.
[EN] DIHYDROOROTATE DEHYDROGENASE INHIBITORS<br/>[FR] INHIBITEURS DE DIHYDROOROTATE DÉSHYDROGÉNASE
申请人:JANSSEN BIOTECH INC
公开号:WO2020144638A1
公开(公告)日:2020-07-16
Disclosed are compounds, compositions and methods for treating diseases, disorders, or medical conditions that are affected by the modulation of DHODH. Such compounds are represented by Formula (I) as follows: wherein R1a, R1b, R2, and R3, are defined herein.
[EN] HSP90 INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DE HSP90 ET LEURS UTILISATIONS
申请人:UNIV BOSTON
公开号:WO2020227368A1
公开(公告)日:2020-11-12
Herein is described the design and synthesis of resorcylate aminopyrazole compounds. These compounds show broad, potent and fungal-selective Hsp90 inhibitory activity. These compounds also find use in treating Hsp90 related deseases.
Design and Synthesis of Fungal-Selective Resorcylate Aminopyrazole Hsp90 Inhibitors
作者:David S. Huang、Emmanuelle V. LeBlanc、Tanvi Shekhar-Guturja、Nicole Robbins、Damian J. Krysan、Juan Pizarro、Luke Whitesell、Leah E. Cowen、Lauren E. Brown
DOI:10.1021/acs.jmedchem.9b00826
日期:2020.3.12
pathogen’s human host, preventing the use of known clinical Hsp90 inhibitors in antifungal applications due to concomitant host toxicity issues. With the goal of developing Hsp90 inhibitors with acceptable therapeutic indices for the treatment of invasive fungal infections, we initiated a program to design and synthesize potent inhibitors with selective activity against fungal Hsp90 isoforms over their